On September 11th Richard Denk from SKAN and Thomas Bühler from Bausch+Ströbel held an interesting webinar about Innovative Aseptic Processing of Antibody-Drug Conjugates.
With four antibody-drug conjugates (ADC) approved by the U.S. Food and Drug Administration (FDA), the development and manufacturing of targeted ADC therapies has become a booming field. Due to the intrinsic complexity of these drug entities, development and manufacturing of antibody-drug conjugates remains very challenging. Strict containment is required to guarantee the protection and safety of both operators and products.
Register here to watch: Webinar